Sichuan Goldstone Asia Pharmaceutical Inc
SZSE:300434
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sichuan Goldstone Asia Pharmaceutical Inc
Revenue
Sichuan Goldstone Asia Pharmaceutical Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sichuan Goldstone Asia Pharmaceutical Inc
SZSE:300434
|
Revenue
¥1.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
24%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Revenue
¥15B
|
CAGR 3-Years
17%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Revenue
¥32.6B
|
CAGR 3-Years
15%
|
CAGR 5-Years
2%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Revenue
¥41.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Revenue
¥22.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Revenue
¥2.5B
|
CAGR 3-Years
53%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
Sichuan Goldstone Asia Pharmaceutical Inc
Glance View
Sichuan Goldstone Asia Pharmaceutical, Inc. engages in the research and development and application of steel reinforced plastic composite pipe technology and machinery. The company is headquartered in Chengdu, Sichuan and currently employs 1,935 full-time employees. The company went IPO on 2015-04-24. Its main products include health products, cracks and small cracks. The firm is also engaged in the machinery manufacturing business, as well as property leasing and management business. Its machinery products mainly include steel reinforced plastic pipe production line, bead winding steel reinforced pipe production line, production line equipment parts and other equipment. The firm mainly operates its businesses in domestic market.
See Also
What is Sichuan Goldstone Asia Pharmaceutical Inc's Revenue?
Revenue
1.1B
CNY
Based on the financial report for Sep 30, 2025, Sichuan Goldstone Asia Pharmaceutical Inc's Revenue amounts to 1.1B CNY.
What is Sichuan Goldstone Asia Pharmaceutical Inc's Revenue growth rate?
Revenue CAGR 10Y
24%
Over the last year, the Revenue growth was -7%. The average annual Revenue growth rates for Sichuan Goldstone Asia Pharmaceutical Inc have been 1% over the past three years , 4% over the past five years , and 24% over the past ten years .
